Consenso multidisciplinar español sobre la profilaxis de la infección respiratoria pediátrica por virus respiratorio sincitial

This publication has 43 references indexed in Scilit:

• An exploration of the use of simple statistics to measure consensus and stability in Delphi studies
  BMC Medical Research Methodology, 2007
• Opinión de los médicos españoles sobre el síndrome de intestino irritable: Resultados de un estudio utilizando el método Delphi
  Revista Española de Enfermedades Digestivas, 2007
• Indicadores de riesgo de morbilidad prevenible causada por medicamentos
  Gaceta Sanitaria, 2007
• Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children
  PharmacoEconomics, 2007
• La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32-35 semanas en España
  Anales de Pediatría, 2006
• Guidelines for the use of palivizumab in infants and young children with congenital heart disease
  Pediatrics International, 2006
• Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain
  Epidemiology and Infection, 2005
• Recomendaciones para la prevención de la infección por virus respiratorio sincitial
  Anales de Pediatría, 2005
• Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
  The Journal of Pediatrics, 2003
• Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry
  Pediatric Pulmonology, 2003